BrainStorm Cell Therapeutics Inc.: NurOwn® autologous cell therapy platform for neurodegenerative diseases. Lead candidate for ALS, Ph2 evaluated 60 ALS pts w favorable safety/tolerability. Ph3 currently enrolling 200 pts across 6 US centers; top-line data expected in mid-2020. Second indication is progressive MS - IND accepted Dec 2018.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Israel
Clinical Stage
Phase III
Disease Space
Central Nervous System, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy
Website:
Address:
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.